News | Rewind Therapeutics

September 2, 2020

Rewind Therapeutics appoints Biopharmaceutical Industry Veteran Kees Been as Non-Executive Director

0 Comments4 Minutes

August 1, 2019

Rewind Therapeutics krijgt VLAIO-subsidie van 2,9 miljoen euro voor het ontdekken en ontwikkelen van nieuwe kandidaat-geneesmiddelen voor myeline-gerelateerde neurologische aandoeningen

0 Comments8 Minutes

August 1, 2019

Rewind Therapeutics awarded €2.9 million VLAIO grant to discover and develop novel drug candidates

0 Comments8 Minutes

February 6, 2019

Rewind Therapeutics expands Scientific Advisory Board with addition of Professors Robin Franklin and Catherine Lubetzki, bringing further expertise in myelin and multiple sclerosis research

0 Comments5 Minutes

October 10, 2018

Rewind Therapeutics Builds Scientific Advisory Board to Accelerate Its Development of New Therapies for Myelin-Related Diseases

0 Comments4 Minutes

October 3, 2018

Rewind Therapeutics Appoints Leading Neuroscience Drug Developer Ian J. Reynolds as Chief Executive Officer

0 Comments3 Minutes

January 4, 2018

Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies

0 Comments2 Minutes

January 4, 2018

Rewind Therapeutics Secures 15.2 M EURO to Develop Novel Remyelination Therapies

1 Comment6 Minutes